Industry news round-up: updates from March 2023
In this latest instalment of our regular monthly column, we summarize a selection of key industry developments that have taken place over the past month.
From Industry
New data supports wearable troponin-I sensor for heart attack diagnosis in real-world settings
A ground-breaking study using a wrist-worn troponin-1 sensor developed by RCE was presented on March 6 as a late-breaking clinical trial at the American College of Cardiology (ACC) annual meeting and simultaneously published online in the European Heart Journal Digital Health.
OM1 expands its Mental Health and Neuroscience Real-World Data Network with datasets for schizophrenia and bipolar disorder
OM1 announced the development of new real-world datasets from 148,000 people with schizophrenia and bipolar disorder for its Mental Health and Neuroscience Real-World Data Network to empower clinical research and improve patient outcomes.
Amgen announces collaborative real-world study to evaluate association between lipoprotein(a) and cardiovascular risk in African Americans
Amgen launched a community-based partnership with the Association of Black Cardiologists and Morehouse School of Medicine to analyze electronic health records of 5,000 African American individuals in exploration of associations between lipoprotein(a) levels and atherosclerotic cardiovascular disease in this under-represented patient population.
Atropos Health and OMNY Health partner to drive personalized real-world evidence generation
Atropos Health and OMNY Health announce new collaboration — OMNY Health’s vast data portfolio will enhance Atropos Health’s Green Button Informatics Consult Service generation of bespoke real-world evidence prognostograms.
DataTools4Heart project to harness real-world cardiology data across Europe to advance heart disease research and care
European Society of Cardiology announces real-world cardiology data from millions of people in multiple European countries will be accessed by the artificial intelligence based DataTools4Heart project to investigate questions in heart disease research and care.
Truveta and Alpine Immune Sciences announce partnership to accelerate recruitment to povetacicept clinical trials
Daily updated real-world clinical data from the Truveta community of 28 health systems will speed identification and recruitment of participants to clinical trials of povetacicept, Alpine’s dual B cell cytokine antagonist.
From the Regulators and HTA
First DARWIN EU® real-world evidence studies conducted and call for new data partners
European Medicines Agency reports the inaugural four real-world data studies of DARWIN EU®, the Data Analysis and Real-World Interrogation Network, and invites expressions of interest from potential second round data partners.
What next for QALYs in US drug value assessments?
If approved by Congress, new legislation in the US could lead to a ban on federal agencies using quality-adjusted life years (QALYs) in drug value assessments.
The debate over QALYs in US drug value assessments continues
In response to the Protecting Health Care for All Patients Act introduced into US legislation earlier this month that would prohibit federal agencies from using quality-adjusted life years (QALYs) in drug value assessments, many stakeholders have voiced their views on the highly polarized topic.
